SUBSCRIBE
SUBSCRIBE

Longboard Pharmaceuticals

NEWS
Pictured: Bar and line graphs showing increasing t
Drug Development
Longboard Stock Skyrockets on Positive Epilepsy Data, Plans $150M Public Offering
Patients treated with Longboard Pharmaceuticals’ bexicaserin saw a 32.5% drop in the frequency of countable motor seizures relative to placebo in a Phase 1b/IIa study. The company’s shares soared 316% Tuesday on the news.
January 3, 2024
 · 
2 min read
 · 
Tristan Manalac
IN THE PRESS
FDA
Longboard Pharmaceuticals Receives Breakthrough Therapy Designation for Bexicaserin (LP352)
July 1, 2024
 · 
7 min read
Biotech Beach
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - June 03, 2024
June 3, 2024
 · 
5 min read
Business
Beacon Biosignals Selected by Longboard Pharmaceuticals to Advance Understanding of Epilepsy and Related Conditions
May 13, 2024
 · 
2 min read
Biotech Beach
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - May 06, 2024
May 6, 2024
 · 
5 min read
Business
Longboard Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Updates
May 2, 2024
 · 
10 min read
Biotech Beach
Longboard Pharmaceuticals to Present Late-Breaking Data from the PACIFIC Study at the American Academy of Neurology (AAN) Annual Meeting on April 15
April 3, 2024
 · 
6 min read
Biotech Beach
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - April 02, 2024
April 2, 2024
 · 
5 min read
Business
Longboard Pharmaceuticals Reports Full Year 2023 Financial Results and Provides Corporate Updates
March 12, 2024
 · 
12 min read
Biotech Beach
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - March 01, 2024
March 1, 2024
 · 
6 min read
Biotech Beach
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - February 02, 2024
February 2, 2024
 · 
6 min read
Load More
JOBS